Reimbursement for the use of generic and second line drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV

Document first published:
Page updated:
Topic:
,
Publication type:

NHS England will routinely reimburse the drug costs associated with pre exposure prophylaxis (PrEP) for the prevention of HIV.

Document

Clinical commissioning policy: Reimbursement for the use of generic and second line drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV

Clinical commissioning policy: Reimbursement for the use of generic and second line drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV

  • PDF
  • 173 KB
  • 5 pages

Summary

This policy is for the use and reimbursement of bio-equivalent generic medicines and second line medicines licenced for PrEP. An exclusion to this policy is reimbursement for the use of the ‘reference’ antiretroviral medicine licenced for PrEP (Truvada ®).

Document

Equality and Health Inequalities Impact Assessment: Reimbursement for the use of generic and second line drugs for Pre Exposure Prophylaxis (PrEP) for the prevention of HIV

Equality and Health Inequalities Impact Assessment: Reimbursement for the use of generic and second line drugs for Pre Exposure Prophylaxis (PrEP) for the prevention of HIV

  • PDF
  • 190 KB
  • 18 pages